Acumen Pharmaceuticals: Clinical-Stage Alzheimer’s Disease Treatment on FDA Fast Track

Clinical-stage biopharmaceutical company, Acumen Pharmaceuticals (Nasdaq: ABOS), continues making strides as it works towards developing a treatment for Alzheimer’s disease. The company’s therapeutic is the first clinical-stage monoclonal antibody designed to selectively target toxic soluble amyloid beta oligomers.

In October 2022, Acumen received Fast Track designation from the FDA for ACU193, underscoring its clinical potential as a potential therapeutic for Alzheimer’s disease.

 Highlights

  • Acumen’s clinical development plan for ACU193 was recently published in the Journal for Prevention of Alzheimer’s Disease.
  • 17 active clinical trial sites are currently recruiting patients in the company’s INTERCEPT-AD clinical trial.
  • The company expects to report topline data from this trial in the second half of 2023.

Acumen ended the third quarter with cash, cash equivalents and marketable securities totaling $200.2 million.

About the Author

Acumen Pharmaceuticals: Clinical-Stage Alzheimer’s Disease Treatment on FDA Fast Track

Editor Investors Prism